Literature DB >> 20233969

NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects.

Janelle A Olson1, Dennis B Leveson-Gower, Saar Gill, Jeanette Baker, Andreas Beilhack, Robert S Negrin.   

Abstract

Natural killer (NK) cells suppress graft-versus-host disease (GVHD) without causing GVHD themselves. Our previous studies demonstrated that allogeneic T cells and NK cells traffic similarly after allogeneic bone marrow transplantation (BMT). We therefore investigated the impact of donor NK cells on donor alloreactive T cells in GVHD induction. Animals receiving donor NK and T cells showed improved survival and decreased GVHD score compared with controls receiving donor T cells alone. Donor T cells exhibited less proliferation, lower CD25 expression, and decreased interferon-gamma (IFN-gamma) production in the presence of NK cells. In vivo, we observed perforin- and Fas ligand (FasL)-mediated reduction of donor T cell proliferation and increased T cell apoptosis in the presence of NK cells. Further, activated NK cells mediated direct lysis of reisolated GVHD-inducing T cells in vitro. The graft-versus-tumor (GVT) effect was retained in the presence of donor NK cells. We demonstrate a novel mechanism of NK cell-mediated GVHD reduction whereby donor NK cells inhibit and lyse autologous donor T cells activated during the initiation of GVHD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20233969      PMCID: PMC2879101          DOI: 10.1182/blood-2009-05-222190

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  40 in total

1.  Cutting edge: murine UL16-binding protein-like transcript 1: a newly described transcript encoding a high-affinity ligand for murine NKG2D.

Authors:  Leonidas N Carayannopoulos; Olga V Naidenko; Daved H Fremont; Wayne M Yokoyama
Journal:  J Immunol       Date:  2002-10-15       Impact factor: 5.422

2.  A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity.

Authors:  Andreas Diefenbach; Jennifer K Hsia; Ming-Yu B Hsiung; David H Raulet
Journal:  Eur J Immunol       Date:  2003-02       Impact factor: 5.532

3.  Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages.

Authors:  A Diefenbach; A M Jamieson; S D Liu; N Shastri; D H Raulet
Journal:  Nat Immunol       Date:  2000-08       Impact factor: 25.606

4.  NK cell functions restrain T cell responses during viral infections.

Authors:  H C Su; K B Nguyen; T P Salazar-Mather; M C Ruzek; M Y Dalod; C A Biron
Journal:  Eur J Immunol       Date:  2001-10       Impact factor: 5.532

5.  Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice.

Authors:  A Cerwenka; A B Bakker; T McClanahan; J Wagner; J Wu; J H Phillips; L L Lanier
Journal:  Immunity       Date:  2000-06       Impact factor: 31.745

6.  Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants.

Authors:  Loredana Ruggeri; Marusca Capanni; Elena Urbani; Katia Perruccio; Warren D Shlomchik; Antonella Tosti; Sabrina Posati; Daniela Rogaia; Francesco Frassoni; Franco Aversa; Massimo F Martelli; Andrea Velardi
Journal:  Science       Date:  2002-03-15       Impact factor: 47.728

7.  Graft-versus-host disease can be separated from graft-versus-lymphoma effects by control of lymphocyte trafficking with FTY720.

Authors:  Yong-Mi Kim; Teviah Sachs; Wannee Asavaroengchai; Roderick Bronson; Megan Sykes
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

8.  Activated, but not resting, T cells can be recognized and killed by syngeneic NK cells.

Authors:  Brian A Rabinovich; Jennifer Li; John Shannon; Rose Hurren; Jan Chalupny; David Cosman; Richard G Miller
Journal:  J Immunol       Date:  2003-04-01       Impact factor: 5.422

9.  In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity.

Authors:  Ryosei Nishimura; Jeanette Baker; Andreas Beilhack; Robert Zeiser; Janelle A Olson; Emanuela I Sega; Mobin Karimi; Robert S Negrin
Journal:  Blood       Date:  2008-06-18       Impact factor: 22.113

10.  Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging.

Authors:  Matthias Edinger; Yu-An Cao; Michael R Verneris; Michael H Bachmann; Christopher H Contag; Robert S Negrin
Journal:  Blood       Date:  2002-09-26       Impact factor: 22.113

View more
  137 in total

Review 1.  Umbilical cord blood immunology: relevance to stem cell transplantation.

Authors:  Syh-Jae Lin; Dah-Chin Yan; Yen-Chang Lee; Hsiu-Shan Hsiao; Pei-Tzu Lee; Yu-Wen Liang; Ming-Ling Kuo
Journal:  Clin Rev Allergy Immunol       Date:  2012-02       Impact factor: 8.667

Review 2.  Targeted immunotherapy for acute myeloid leukemia.

Authors:  Sumithira Vasu; Michael A Caligiuri
Journal:  Best Pract Res Clin Haematol       Date:  2011-11-11       Impact factor: 3.020

Review 3.  Immune modulation of inflammatory conditions: regulatory T cells for treatment of GvHD.

Authors:  Doreen Haase; Mireille Starke; Kia Joo Puan; Tuck Siong Lai; Olaf Rotzschke
Journal:  Immunol Res       Date:  2012-09       Impact factor: 2.829

Review 4.  Immune regulatory cells in umbilical cord blood and their potential roles in transplantation tolerance.

Authors:  Young-June Kim; Hal E Broxmeyer
Journal:  Crit Rev Oncol Hematol       Date:  2010-08-19       Impact factor: 6.312

5.  Changes in T lymphocyte subsets in mice with CT26 colon tumors after treatment with donor lymphocyte infusion.

Authors:  Tao Jiang; Daxun Piao; Anlong Zhu; Hongchi Jiang
Journal:  Tumour Biol       Date:  2014-03-22

6.  CD8+ T Cells and NK Cells: Parallel and Complementary Soldiers of Immunotherapy.

Authors:  Jillian Rosenberg; Jun Huang
Journal:  Curr Opin Chem Eng       Date:  2017-12-14       Impact factor: 5.163

Review 7.  Immune regulatory cell infusion for graft-versus-host disease prevention and therapy.

Authors:  Bruce R Blazar; Kelli P A MacDonald; Geoffrey R Hill
Journal:  Blood       Date:  2018-05-04       Impact factor: 22.113

8.  Prediction of acute GVHD and relapse by metabolic biomarkers after allogeneic hematopoietic stem cell transplantation.

Authors:  Xiaojin Wu; Yiyu Xie; Chang Wang; Yue Han; Xiebing Bao; Shoubao Ma; Ahmet Yilmaz; Bingyu Yang; Yuhan Ji; Jinge Xu; Hong Liu; Suning Chen; Jianying Zhang; Jianhua Yu; Depei Wu
Journal:  JCI Insight       Date:  2018-05-03

9.  Effect of donor KIR2DL1 allelic polymorphism on the outcome of pediatric allogeneic hematopoietic stem-cell transplantation.

Authors:  Rafijul Bari; Piya Rujkijyanont; Erin Sullivan; Guolian Kang; Victoria Turner; Kwan Gan; Wing Leung
Journal:  J Clin Oncol       Date:  2013-09-16       Impact factor: 44.544

10.  MicroRNAs activate natural killer cells through Toll-like receptor signaling.

Authors:  Shun He; Jianhong Chu; Lai-Chu Wu; Hsiaoyin Mao; Yong Peng; Christopher A Alvarez-Breckenridge; Tiffany Hughes; Min Wei; Jianying Zhang; Shunzong Yuan; Sumeet Sandhu; Sumithira Vasu; Don M Benson; Craig C Hofmeister; Xiaoming He; Kalpana Ghoshal; Steven M Devine; Michael A Caligiuri; Jianhua Yu
Journal:  Blood       Date:  2013-04-11       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.